DaubersUP, well, I am, in principle, with Infinity on this one. Apples to apples comparison are to preferred and Co's should try to provide them, if possible. They don't and I must go digging data - I rather sit on my patio bombarding deer eating my sweet young siberian spruces with empty beer cans.
you mean that it is just little old me who would like to have reasonably comparable data to think about? That when a pharmaceutical company thinks about buying into the prurisol program they do not care about results being transparent and "apple to apple"?
That is all they care about- the science, right? the reason we are all here.
And IP should be up front, totally with us and with them O/w it looks like they are hiding something
But I guess there are enough shareholders content with apples to oranges comparisons. but those people will not be making deals for IP drugs-